Clinical Trials
17 trialsNCT07620574 2026-06-02
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Phase 3 Not yet recruiting
NCT07284394 2026-05-26
PACHA-02
UNICANCER
Phase 3 Not yet recruiting
NCT07595276 2026-05-19
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3 Not yet recruiting
NCT07525206 2026-04-13
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Not yet recruiting
NCT07362836 2026-01-23
Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
Fudan University
Phase 3 Not yet recruiting
NCT07340567 2026-01-14
CIRCULATEIII
UNICANCER
Phase 3 Not yet recruiting
NCT07271355 2025-12-09
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
Phase 3 Not yet recruiting
NCT06783491 2025-11-24
FOXHIPECT4
Maimónides Biomedical Research Institute of Córdoba
Phase 3 Not yet recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT06839092 2025-07-30
PROPAC
University Hospital, Geneva
Phase 3 Not yet recruiting
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07004413 2025-06-04
FIRE-11
Charite University, Berlin, Germany
Phase 3 Not yet recruiting
NCT06616259 2024-09-27
CAPCET-III
West China Hospital
Phase 3 Not yet recruiting
NCT06343116 2024-04-02
NOTABLE-308
Biotech Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT05948072 2023-07-17
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
Fudan University
Phase 3 Not yet recruiting
NCT05699746 2023-01-26
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Zhejiang University
Phase 3 Not yet recruiting
NCT05427669 2022-10-07
AFFORD
Sun Yat-sen University
Phase 3 Not yet recruiting